Myeloperoxidase G-463A polymorphism and the risk of gastric cancer: a case-control study. Carcinogenesis 27

Several epidemiological studies have shown that the myeloperoxidase (MPO) G–463A polymorphism may influence the risk of many cancers, including lung, breast, bladder and laryngeal cancer. However, there is no study concerning the MPO polymorphism and gastric cancer risk. In this hospital-based, case–control study, we used polymerase chain reaction–restriction fragment length polymorphism protocols to examine the prevalence of MPO G–463A polymorphism in gastric cancer. A signifi-cantly different distribution of the MPO –463G/A geno-type was demonstrated among the cases and controls (c2 7.42, P 0.03). Subjects with the variant genotypes (the sum of GA and AA) had a 44 % reduced risk of gastric cancer relative to those with GG [adjusted odds ratio (OR) 0.56; 95 % CI: 0.32–0.97]. Stratified analyses revealed that the protective effect of A allele wa